Xilio Therapeutics (Xilio Therapeutics) Cash-to-Debt : 3.58 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Xilio Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.58.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Xilio Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Xilio Therapeutics's Cash-to-Debt or its related term are showing as below:

XLO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91 Med: 3.58 Max: 9.64
Current: 3.58

During the past 5 years, Xilio Therapeutics's highest Cash to Debt Ratio was 9.64. The lowest was 0.91. And the median was 3.58.

XLO's Cash-to-Debt is ranked worse than
59.39% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs XLO: 3.58

Xilio Therapeutics Cash-to-Debt Historical Data

The historical data trend for Xilio Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Xilio Therapeutics Cash-to-Debt Chart

Xilio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

2.62

0.91

9.64

6.04

3.58

Xilio Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											6.04	5.15	4.49	4.16	3.58

Competitive Comparison of Xilio Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Xilio Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xilio Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Xilio Therapeutics's Cash-to-Debt falls into.

Xilio Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Xilio Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	44.704	/	(4.362	+	8.142)
	=	3.58

Xilio Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	44.704	/	(4.362	+	8.142)
	=	3.58

Xilio Therapeutics (NAS:XLO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Xilio Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Xilio Therapeutics (Xilio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Winter Street, Suite 300, Waltham, MA, USA, 02451

Website

https://www.xiliotx.com

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.

Executives

Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova	officer: Chief Medical Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield	officer: Chief Operating Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan	officer: SVP, FINANCE AND ACCOUNTING	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English	officer: Principal Accounting Officer	828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp	10 percent owner	71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p.	10 percent owner	101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105